Hated pharma executive Martin Shkreli has a personal wealth of at least $45 million.
That little detail was revealed after it was determined that Shkreli used a personal E*Trade account with a $45 million balance to secure his release on a $5 million bond.
Shkreli is best known for hiking the price of life-saving drug Daraprim by more than 5,000% while CEO of Turing Pharmaceuticals.
Shkreli was indicted in December on charges that he uses his former company, Retrophin, as his own personal piggy bank.
Shkreli “ensnared investors through a web of lies and deceit” and ran Retrophin like a Ponzi scheme, U.S. Attorney Robert Capers said at the time.
Shkreli continues to maintain his innocence, claiming that the federal government is going after him because of the drug price hike.
Despite being deemed “the most hated man in America” by various members of the press, Shkreli has continued to defend his decision to rapidly increase the price of the 60-year-old drug his company only recently acquired.
More information about Martin Shkreli’s net worth has not been revealed at this time.